Table 1.
Animals divided by treatment group.
| Age | Sex | Weight | Infection | Treatment | Week of rebound | Rebound VL (copies/ml) | Tissue collected | |
|---|---|---|---|---|---|---|---|---|
| LE46 | 3.98 | M | 7.80 | IV | None | N/A | N/A | Yes |
| LF12 | 3.91 | M | 10.85 | IV | None | N/A | Yes | |
| JK78 * | 6.74 | F | 9.45 | IVAG | None | N/A | No | |
| FF62 | 13.68 | F | 13.25 | IVAG | None | N/A | No | |
| LA22 | 4.54 | M | 9.50 | IV | None | N/A | Yes | |
|
| ||||||||
| Average | 6.57 | 10.17 | ||||||
|
| ||||||||
| GA95 | 12.6 | F | 8.20 | IVAG | bNAbs | – | <200 | No |
| HM84 | 9.78 | F | 5.90 | IVAG | bNAbs | 15 | 2000 | No |
| IN59 | 8.46 | F | 9.50 | IVAG | bNAbs | 14 | 200 | No |
| JA12 | 7.78 | F | 9.30 | IVAG | bNAbs | 12 | 230 | No |
| KC14 | 6.03 | M | 8.94 | IV | bNAbs | 16 | 230 | Yes |
| LA30 | 4.18 | M | 9.13 | IV | bNAbs | 14 | 3100 | Yes |
| KT51 | 4.88 | M | 9.35 | IV | bNAbs | 19 | 200 | Yes |
| KJ36 | 5.19 | M | 7.60 | IV | bNAbs | 14 | 16,000 | Yes |
|
| ||||||||
| Average | 6.61 | 8.53 | ||||||
|
| ||||||||
| KE78 | 5.96 | M | 10.02 | IV | bNAbs + Rh-α4β7 | – | <200 | Yes |
| JT94 | 6.75 | M | 9.60 | IV | bNAbs + Rh-α4β7 | – | <200 | Yes |
| KL18 | 5.06 | M | 8.20 | IV | bNAbs + Rh-α4β7 | 16 | 630 | Yes |
| LB74 | 4.03 | M | 9.70 | IV | bNAbs + Rh-α4β7 | 15 | 7500 | Yes |
| KB22 | 6.5 | M | 12.10 | IV | bNAbs + Rh-α4β7‡ | – | <200 | Yes |
| KG31 | 6.34 | M | 11.35 | IV | bNAbs + Rh-α4β7‡ | 18 | 320 | Yes |
| KL59 † | 5.59 | M | 9.84 | IV | bNAbs + Rh-α4β7‡ | 15 | 30,000 | Yes |
|
| ||||||||
| Average | 5.75 | 10.12 | ||||||
*
Mamu-A*01+.
†
Excluded because of high antidrug antibodies.
‡
Week 11/14.
IVAG, intravaginal; IV, intravenous; N/A, not applicable.